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Abstract
Extensive changes in cannabis regulation accompany changing public attitudes toward 
cannabis use and legalization. Cannabis use is more prevalent when the drug is legal; 
therefore, there is a substantial need for an evidence-based understanding of the risks 
associated with cannabinoids. The current chapter reviews the definition of CUD, its 
prevalence and associated conditions, and the contemporary understanding of its causes 
to inform policy, prevention efforts, and treatment of CUD in a dynamic and evolv-
ing legislative landscape. Studies are currently limited by an absence of standardized 
methods to characterize cannabis consumption levels as well as compound composition. 
Understanding the harms associated with cannabis use and CUD will be fundamental in 
informing policy and supporting clinicians.
Keywords: cannabis, addiction, withdrawal, prevalence, neurobiology, neurocognition, 
motivation, comorbidities
1. Introduction
The term ‘cannabis’ refers to any product from plants of the cannabis genus, including mari-
juana and hashish, which are used primarily for their reinforcing effects. The main psychoac-
tive compound in cannabis is ∆9-tetrahydrocannabinol (THC); however, more than 100 other 
cannabinoids have been identified [1]. Other compounds include cannabidiol, cannabinol and 
cannabigerol; there is some evidence for protective effects of cannabidiol on THC’s effects 
[2–4]. In a major shift from the ‘war on drugs’ campaigns that characterized the 1980s, legal-
ization of cannabis for medicinal and recreational purposes is spreading across Canada and 
the United States. These extensive changes in cannabis regulation accompany changing pub-
lic attitudes toward cannabis use and legalization [5]. Cannabis use is more prevalent when 
the drug is legal [5], therefore with the widespread social and legislative changes, there is a 
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substantial need for an evidence-based understanding of the risks associated with cannabi-
noids. Of particular concern is a potential rise in the development of cannabis use disorder 
(CUD), the psychiatric diagnosis of addiction to cannabis, and it is still unclear how legaliza-
tion of the drug relates to the prevalence and severity of CUD [6]. Here we review the defini-
tion of CUD, its prevalence and associated conditions, and the contemporary understanding 
of its causes to inform policy, prevention efforts and treatment of CUD in a dynamic and 
evolving legislative landscape.
2. Definition of CUD
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) [7] 
defines CUD as any 2 of 11 diagnostic criteria (Table 1), which include hazardous use of 
the drug (e.g. driving while under the influence), taking the drug in larger/longer amounts 
than intended, preoccupation with cannabis, unsuccessful efforts to cut down, drug toler-
ance, neglecting major roles to use, and social/interpersonal problems related to use. While 
the DSM-IV included two categories, including both abuse (putatively lower severity) and 
dependence (putatively higher severity), research supports a dimensional one-factor model, 
indicating that CUD can best be described as a unidimensional construct [8]. The number of 
endorsed criteria serves as a disorder severity marker: mild (2–3 criteria), moderate (4–5 crite-
ria) and severe (6+ criteria) CUD [7]. Criteria for craving as well as withdrawal were added in 
the DSM-5, with 60% endorsement of craving and over 30% reporting withdrawal symptoms 
in past-year individuals with CUD [9].
3. Cannabis withdrawal syndrome
While it is popularly reported that there are no withdrawal effects from cannabis, there is evi-
dence for withdrawal symptoms in CUD that are comparable to nicotine withdrawal in mag-
nitude and consequences [10, 11]. The DSM-5 now includes a Cannabis Withdrawal Syndrome 
[7] which consists mostly of emotional and behavioral symptoms including anxiety, irritabil-
ity, restlessness, depression, anger, as well as sleep, weight and appetite disturbances [12]. 
Less common physical symptoms include stomach pain, shakiness and sweating [12]. The 
clinical significance of the withdrawal syndrome was originally questioned; however, those 
symptoms are linked with increased functional impairment in normal daily activities [13]. The 
delayed onset of the withdrawal syndrome may explain why it is often overlooked: symptoms 
peak 2–3 days after cessation of heavy cannabis use and can last 2–3 weeks [12, 14]. Given the 
daily use of many individuals with CUD, they may not notice the symptoms. Withdrawal 
symptoms are nevertheless closely linked to relapse: most abstinent individuals experienc-
ing withdrawal symptoms will take the drug to alleviate symptoms, thereby perpetuating 
cannabis use [15, 16]. The withdrawal syndrome is also important in medicinal cannabis use. 
Notably, cannabis withdrawal symptoms overlap with mood and anxiety disorder symptoms 
[7]—the very symptoms that some cannabinoid products are posited to treat. Many individu-
als cite mood modification as a motivation for cannabis use and are unaware that their short 
term use for symptomatic relief may result in a long-term withdrawal syndrome [17]. More 
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generally, medicinal cannabis can be thought of as no different than other medications for 
which the pharmacology results in physiological dependence including a withdrawal syn-
drome (e.g., benzodiazepines and opioids), requiring clinical consideration and management. 
Indeed, the same is true for its abuse liability in the context of CUD.
4. Prevalence of cannabis use and cannabis use disorder (CUD)
Cannabis remains the most commonly used illicit* (*state/country-dependent) psychoactive 
drug. Large epidemiological studies show that ~43% of individuals in the US and Canada 
report having tried cannabis, with ~35% having tried it more than once [18–20]. Cannabis use 
Table 1. Diagnostic criteria for cannabis use disorder in the Diagnostic and Statistical Manual of the American Psychiatric 
Association (5th edition).
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is highest in adults (ages 18–44), with just over half reporting using cannabis [18]. Past-year 
cannabis use in emerging adult populations (18–24 years-olds) is around 33.3%, with daily 
use almost 4% in this age group [18, 19].
Cannabis use prevalence rates from 2002 to 2012 show overall increases across North America 
[5, 18, 19, 21] and, increases in use and frequency of use coincide with declining risk percep-
tions of the drug [5]. Nevertheless, cannabis use trends differ longitudinally across specific 
age groups. For example, since 2002, prevalence rates appear to have increased in adults aged 
25–44 (from 14 to 15.6%), remained stable in 18–24 year olds (around 33%) and decreased in 
the 15–17 age range (from 28.5 to 20%) [18, 19].
Prevalence rates for cannabis use disorder (CUD) range from 2.9% up to 19%—with approxi-
mately 13 million individuals worldwide meeting criteria [9, 22, 23]. Severe lifetime CUD 
rates are around 2%, with rates peaking during the emerging adulthood period (~21 years of 
age) [9]. There are also sociodemographic differences in prevalence rates—lifetime CUD rates 
are almost twice as high in males versus females, in adults 18–29, with a mean age of onset 
in the early twenties [9]. Unmarried individuals and those with lower socio-economic status 
report higher CUD prevalence rates; however, education appears largely unrelated [9].
One large epidemiological study in the United States also suggests that CUDs doubled 
between 2002 and 2012 [21], but not all longitudinal studies report the same prevalence trends 
in CUD [5, 20, 21, 24]. Discrepant prevalence rates may relate to underreporting in earlier 
studies as social acceptance of cannabis use increases [25]. Indeed, there are notable sociocul-
tural influences on harm perception and willingness to acknowledge CUD symptoms varies 
between legal cultures [26]. Endorsement of CUD criteria can differ between countries and 
may relate to legalization status. For example, reports of failed quit attempts and withdrawal 
symptoms differ between the US and Netherlands [26, 27].
Importantly, CUD is associated with high levels of disability, including social and emotional 
functioning and greater CUD severity is associated with increasing levels of disability [9]. 
Information on cannabis-related disability is fairly new, as many previous studies did not 
include cannabis when studying disease burdens, but newer studies demonstrating that CUD 
can produce more years with disability [28]. Disability can persist even after CUD remission, 
although the reason for this is not yet clear [29]. It is also important to note that cannabis use 
and misuse (more broadly than just CUD) are associated with significant economic costs. In 
Canada, the estimated economic burden of cannabis use was 2.8Bn in 2014 and cannabis costs 
exhibited the largest increase among substances from 2007 to 2014, a 19.1% increase [30].
Finally, it is important to contextualize cannabis with other psychoactive drugs. One way 
to quantify addiction liability across substances is to examine the proportion of individu-
als who develop a substance use disorder, such as CUD, relative to the number of indi-
viduals who have at least tried a given substance. Using this metric in the large National 
Epidemiologic Survey on Alcohol and Related Conditions (NESARC) cohort, fewer than 
one in ten (8.9%) individuals transitioned from any cannabis use to cannabis dependence 
(pre-DSM-5), which was lower than tobacco, alcohol, and cocaine [31]. Another way to con-
textualize relative risk is to consider the conditional probability between use and misuse 
(i.e., the proportion of active users of a given drug that have a diagnosable problem). Again, 
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drawing on large-scale NESARC data, 7.96% of cannabis users met criteria for cannabis 
dependence, which was higher than alcohol (5.82%) but substantially lower than tobacco 
(46.13%), heroin (26.96%), and cocaine (23.91%) [32]. In an interesting study of addiction 
experts using a multi-criteria decision analysis to judge substance use harms, cannabis was 
ranked 8th out of 20, behind alcohol, heroin, crack cocaine, methamphetamine, cocaine, 
tobacco, and amphetamine (in that order). Collectively, these findings suggest that although 
cannabis is far from without risk, it can also be thought of as lower risk than a number of 
other psychoactive drugs, both legal and illegal.
5. Common comorbidities
Other comorbid conditions are common in CUD; in particular, high rates of depression, 
anxiety, substance use and personality disorders are consistently associated with CUD [5, 9]. 
Understanding associations between CUD and other disorders is important as it provides 
more information on course and progression of the disorder.
Other substance use disorders (SUDs) are most commonly associated with CUD, with greater 
lifetime use of illicit drugs, including sedative/tranquilizers, painkillers, cocaine stimulants, 
club-drugs, hallucinogens, inhalant/solvents, heroin and other prescription drugs [33]. Recent 
epidemiological studies suggest increasing links with stimulant-based substances including 
MDMA, methamphetamine and prescription stimulants such as Ritalin [33]. It is possible 
that cannabis and stimulant co-abuse patterns represent individuals counterbalancing each 
drug’s pharmacokinetic effects; for example applying sedative effects of cannabis following 
stimulant use [33]. Individuals with CUD are also more likely to also be current smokers and 
report high rates of alcohol use [9, 33]. Longitudinal studies are now providing more support 
for a causal relationship between early cannabis use and CUD as well as substance use and 
other psychiatric disorders. One large study demonstrated consistent, dose-response charac-
teristics between early cannabis use and the development of CUD, other illicit substance use, 
depression and suicide attempts [34]. Altogether consistent data show polydrug use with 
CUD even when controlling for other health and psychiatric factors present before or during 
adolescence [33, 34].
In terms of other conditions, personality disorders are highly comorbid, in particular increased 
rates of antisocial and borderline personality disorder are noted [9]. Anxiety disorders are 
also linked to CUD, with Post Traumatic Stress Disorder (PTSD) most highly associated, fol-
lowed by general anxiety and panic disorder [9, 21]. Applying the CUD severity specifiers 
(mild, moderate, severe) shows that increasing CUD severity is associated with the increas-
ing strength of associations with these psychiatric conditions [21]—similar to CUD, clinical 
problems also exist on a severity continuum [5].
Converging lines of preclinical, epidemiological and experimental studies demonstrate 
strong links between cannabinoids and psychosis. The exogenous cannabinoid hypothesis 
posits that cannabinoid exposure is linked to the development of psychosis [35]. In controlled 
human laboratory settings, THC and cannabis extract administration produces increased pos-
itive symptoms, (including delusions, suspiciousness and perceptual alterations), negative 
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symptoms (including blunted affect, psychomotor retardation, reduced rapport), cognitive 
deficits (including learning, memory and attention),—some of which are related to schizo-
phrenia including verbal recall impairment with increased “false positives” and “intrusions” 
[36]. In healthy individuals, these acute laboratory effects of cannabis are time-locked to drug 
administration, dose-related and transient [36].
Consistent with acute intoxication experiments, epidemiological studies also provide strong 
evidence for cannabis use increasing the risk for psychosis, even after adjusting for covari-
ates [37]. While these studies have difficulty demonstrating a causal relationship with psy-
chotic disorders, a growing number of longitudinal prospective studies are beginning to 
demonstrate these links [37]. There is still more research needed integrating neurobiology, 
epidemiology and psychopharmacology with particular compounds and potencies (includ-
ing synthetic cannabinoids) to determine the magnitude and mechanisms of a causal effect 
[37]. Nevertheless, many individuals who use cannabis regularly do not develop psychotic 
disorders, therefore understanding those subgroups most at risk to propsychotic effects still 
needs to be clarified [35].
These findings have significant implications for treatment; high comorbidity rates underscore 
the fact that clinicians should screen for other conditions as these are likely present. Additionally, 
treatment approaches may need to target concurrent conditions. The co-relationship between 
CUD and other conditions is also important if CUD prevalence increases with legislative 
changes. While the causal relationship between these co-occurrences is not yet definitive, the 
close association nonetheless highlights important vulnerabilities and speaks to the importance 
of prevention and early intervention efforts.
6. Contemporary biopsychosocial model of etiology
Most individuals who try cannabis do not use it regularly or progress to CUD; therefore 
cannabis use alone is not sufficient to develop a CUD. Modern etiological theories of CUD 
emphasize neurophysiological adaptations that occur with persistent cannabis use, resulting 
in changes in cognition and motivation that recursively sustain drug-seeking, and important 
developmental features in which early cannabis use can create vulnerabilities for subsequent 
misuse and CUD.
6.1. Neurobiology and neurocognition
The endocannabinoid system in the brain modulates the activity of multiple neurotransmit-
ters, including dopamine, through the cannabinoid receptor 1 (CB1) [38].
Most of the rewarding effects of cannabis are mediated through THC at the cannabinoid CB1 
receptor in the brain [39–41]. These feelings of high relate to THC concentrations and can 
be blocked by a CB1 antagonist [42]. Additionally, there is evidence for the CB1 receptor in 
the development of dependence and in the withdrawal syndrome [39]. The brain responds 
to persistent cannabis consumption and the resulting circulating THC by homeostatically 
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downregulating CB1 receptors [43]; full recovery of CB1 receptor density has been detected 
after one-month abstinence and substantial recovery has been detected as soon as 72-hours 
[43, 44].
Both the acute and chronic effects of cannabis on the central nervous system are not well-
understood in humans. CB1 receptors are heavily expressed in the striatum, hippocampus, 
amygdala and prefrontal cortex (PFC) and it is mostly in these regions that regular cannabis 
users show altered neuroanatomy [45]. Understanding neuroanatomic alterations with can-
nabis use is complicated by this drug’s composition changes in recent years including differ-
ent cannabinoid compounds with unique neural effects [45]. Since the 1990s, THC potency 
has increased from 4 to 12%; simultaneously, the average concentration of THC to cannabi-
diol has increased almost 80 times, suggesting plants are now bred with much higher THC 
concentrations (based on confiscated cannabis materials) [46]. These compound alterations 
are important as preclinical evidence suggests neurotoxic effects of THC on CB1 rich areas 
[45]. In humans, volumetric reductions and gray matter density alterations are consistently 
noted in the hippocampus, which relate to duration of use and cannabis dosage [45, 47, 48]. 
There are also links with compound composition; THC levels are inversely related to volu-
metric reductions while higher THC/cannabidiol ratios are associated with reduced volume 
and gray matter [45]. There is some evidence for neuroprotective cannabidiol effects as indi-
viduals with high cannabidiol levels do not show hippocampal volume reductions, however 
the mechanisms by which cannabidiol might offset THC effects are currently unknown [45].
Outside of the hippocampus, neuroanatomic alterations are additionally noted in high-density 
CB1 areas including the amygdala and striatum, PFC, parietal cortex, insula and cerebellum 
[45]. Altogether, these neuroanatomic alterations may result from THC metabolites accumu-
lating and producing neurotoxic effects, cannabinoid receptor adaptations and/or changes in 
cells or vascularity [45]. All of these CB1-rich areas serve core functions in memory, attention, 
learning and reward and cognitive control. The hippocampus, PFC and amygdala are central 
in cognitive processing, indeed behavioral/functional impairments are noted in memory, 
attention and learning in CUD [49].
6.2. Cognitive functioning
Although the findings are mixed, overall subtle neurocognitive deficits in executive function, 
memory and learning are found with cannabis exposure, however, long term cannabis effects, 
and whether they are reversible, are still unclear [49, 50]. The ability to hold and manipulate 
information is consistently impaired with acute cannabis administration, although few stud-
ies report long-term working memory problems [50–53]. Diminished prefrontal cortex and 
hippocampal activity are noted during memory tasks in heavy cannabis users [54].
Of particular relevance to cannabis is the role of impulsivity—a systematic review provides 
support for alterations in inhibitory control in heavy cannabis users [55].
There are mixed behavioral findings when examining attention and concentration in CUD 
as well as impulsive behaviors following acute administration, short-term and long-term 
abstinence [50]. Nevertheless several neuroimaging studies demonstrate reduced prefrontal, 
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anterior cingulate and dorsolateral PFC activity during inhibitory control tasks [56–58]. Delay 
discounting, a behavioral economic measure of impulsivity reflecting preferences for smaller 
immediate rewards relative to larger delayed rewards, has been inconsistently associated 
with CUD, although a recent meta-analysis detected an overall small magnitude association 
[59]. This is consistent with greater impulsivity on this measure in relation to other forms of 
addiction, ADHD, and obesity [60–62].
Decision-making and risk-taking appear altered following acute cannabis administration as 
well as after short-term and longer-term abstinence [50]. It is yet unclear whether these effects 
are short-term or long-lasting or if these represent an exposure effect; while some studies 
report reversible findings following abstinence [63, 64] others report deficits even years after 
drug cessation, suggesting cumulative drug effects [65, 66]. Mixed findings again may relate 
to the changing compound profile of cannabis—most findings reported from acute intoxica-
tion experiments to date administer cannabis concentrations ~3% THC—significantly lower 
levels than the 12% rate often found in current samples [46]. Longitudinal studies with more 
potent drugs and more systematic control for cannabis use will be critical to clarify the effects. 
It is also possible that neurocognitive alterations exist prior to cannabis use; however, few 
longitudinal studies exist testing this hypothesis.
Clarifying neurocognitive impairments associated with CUD is important for understanding 
how the disorder progresses and impacts specific functions. To date, few studies examine 
how these impairments relate to recovery and abstinence. Understanding these impairments 
is also important for clinicians; particular deficits may put into question the usefulness of cog-
nitive therapy [67] as specific cognitive functions may underlie learning adaptive responses 
and skills in behavioral therapies and avoiding relapse [50].
To date, functional neuroimaging studies examining the underlying neural substrates of these 
executive functions provide some evidence for altered processing [2, 50, 54, 56–58, 66]. Mixed 
findings may relate to the neuroimaging techniques employed, the constructs examined and 
the heterogeneity of characteristics in the samples studied.
6.3. Motivation and cannabis
One of the effects of chronic cannabis use in popular culture is changes in motivation. A 
recent longitudinal study showed cannabis use predicted lower persistence and initiative in 
college students [68]. Nevertheless, only a handful of studies have systematically examined 
cannabis’ effects on motivation under controlled conditions. Laboratory studies of cannabis 
on motivation have found pro-motivational effects [69, 70], amotivational effects [71], or no 
effect [72]. These mixed findings may relate to problematic methodology, including differing 
cannabis doses (even within the same study), small sample numbers (e.g. N = 5), cross sec-
tional designs, and differing compound composition over time. The heterogeneity of the can-
nabis users sampled in the studies is quite diverse; indeed, most human studies in cannabis 
users compare groups of cannabis users with varying levels of cannabis related problems (e.g. 
heavy, regular, occasional, light) to controls without assessing CUDs with rigorous diagnostic 
instruments. Additionally, some of the simple finger-tapping tasks that participants are asked 
to perform in the laboratory may not adequately capture the affected motivated behavior.
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A recent study examining chronic effects of cannabis on reward learning, found that non-
intoxicated individuals with CUD did not develop a response bias to reward-paired cues over 
time, suggesting an impaired ability to learn new rewards [73]. The neurobiology underlying 
impaired reward learning in CUD is currently not clear, including whether this is a predispos-
ing factor or a result of heavy cannabis use. Nevertheless, the inability to form new reward 
associations lies at the core of an amotivational syndrome.
There is also evidence for heterogeneity of effects of different active cannabis concentrations 
and compounds. On another task examining effort-related decision-making, acute admin-
istration of cannabis with or without cannabidiol reduced the number of effortful choices 
for monetary reward compared to placebo [73]. Although the effortful choices were not dif-
ferentially affected by the presence of cannabidiol in the compound, the investigators found 
that following cannabis administration with cannabidiol, the expected value of the reward 
(measured as the outcome value X the probability of receiving that outcome) increased the 
likelihood of making a high-effort choice. These results suggest that the presence of cannabi-
diol may affect THC’s effects on processing expected value [73].
Amotivation in CUD may reflect that cannabis itself becomes a predominant motivator over 
other stimuli. One study investigated neural sensitivity to hedonic stimuli and showed that 
long-term daily users showed greater neural responses in reward networks to cannabis 
cues, relative to natural reward (fruit) cues [74]. Moreover, activity in frontostriatal tempo-
ral regions correlated with subjective reports of craving, THC metabolite levels as well as 
cannabis withdrawal scores. These findings suggest a hyper-responsivity and specificity of 
the brain’s response to cannabis cues in heavy users. Additionally, the positive relationship 
between THC levels and neural response suggests that the latter may relate to cannabis use 
[74]. Another large longitudinal fMRI study prospectively examined striatal changes follow-
ing cannabis use in youths at the ages of 20, 22, to 24 [75]. The striatum is a key node of the 
reward network that signals the motivational significance of a stimulus [76]. The results in 
youths showed that past-year cannabis use at each of the 3 scans related to striatal activation 
during reward anticipation, even when covarying for binge drinking or other drug use [75]. 
At the first scan, past-year cannabis use negatively correlated with striatal activation at Time 
2, while past-year cannabis use at Time 2 was negatively associated with striatal activation 
at Time 3. Importantly, blunted striatal response was only present in those individuals with 
escalating drug use, suggesting that cannabis may be triggering these changes. Overall, this is 
the first study to show longitudinal associations between cannabis use and striatal activation 
during a nondrug reward anticipation task. More prospective studies are needed to evaluate 
whether an amotivational syndrome exists and the mechanisms by which it might develop.
6.4. Developmental influences
Given their increased drug experimentation, combined with a developing endocannabinoid 
system, adolescents represent a population particularly vulnerable to cannabis’ effects [77, 78]. 
A meta-analysis of cognitive functioning in adolescents reported reduced cognitive function-
ing with frequent or heavy cannabis use, however, abstinence greater than 72 hours appears 
to diminish this effect [79].
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To date, few neuroimaging studies examine adolescent populations with CUD. Adolescent 
chronic cannabis use is associated with greater performance-related activation in fronto-
temporal areas, despite similar performance, suggesting neuroadaptations, or greater neural 
effort to perform memory and inhibition tasks [56]. A recent prospective cohort study scanned 
adolescents as they performed a working memory task prior to and after their first cannabis 
exposure [80]. The researchers found that those youths that would go on to use cannabis by 
the age of 15 (follow up), showed increased frontoparietal activity at baseline relative to the 
non-using group—these neural differences remained unchanged or increased when exam-
ined longitudinally. This is the first study to demonstrate frontoparietal and neurocognitive 
alterations prior to cannabis use. The researchers also found that at 12 years of age (baseline), 
the adolescents who would go on to use cannabis by the age of 15 (follow-up) had signifi-
cantly lower scores on the cognitive battery. The difference scores on the cognitive battery 
from baseline to follow-up did not change, suggesting no significant neurocognitive changes 
following cannabis initiation. This prospective cohort study is one of the first to demonstrate 
specific neurocognitive features that may exist prior to cannabis exposure.
Given the changing compound composition of cannabis, combined with increasing THC levels 
and availability, understanding the effects of cannabis use on the brain and on memory, learn-
ing and reward processing should be a priority in adolescents. Accordingly, the Adolescent 
Brain Cognitive Development (ABCD) study recently launched by the National Institute of 
Health in the United States will follow 10,000 children longitudinally with multiple measures 
of neural, cognitive and emotional functioning [81]. This prospective cohort study will pro-
vide much-needed information on the long-term effects of cannabis use.
7. Other harms from cannabis
With the exception of nicotine, smoked cannabis includes many of the same chemicals and 
carcinogens found in tobacco that can damage lung tissue [82]. Heavy cannabis smoking 
is associated with chronic bronchitis and inflammation/injury in the larger airways [82]. 
Findings for other types of lung diseases and cancers are mixed, given high rates of comorbid 
tobacco use in regular cannabis users. Some of the chronic respiratory effects appear revers-
ible, particularly in those individuals who only smoke cannabis [83, 84]. The impact of can-
nabis use on lung health may also change, as other methods of intake are gaining popularity, 
such as vaping or edibles [82].
One of the largest public health concerns with legalization of cannabis use is the effect of the 
drug on driving. Driving simulation studies show a relationship between blood THC levels 
and impaired performance, particularly with reaction time and lane position variability (i.e., 
weaving) [85]. One study had occasional cannabis smokers perform a visuomotor tracking 
task while undergoing fMRI after taking low-dose THC and found decreased psychomo-
tor skills as well as reduced activity in fronto-parietal areas [86]. After alcohol, cannabis is 
the most commonly reported drug in driving accidents and fatalities [87]. There is current 
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ongoing research to better understand drug interactions, particularly with alcohol, as psy-
chomotor impairments appear more severe when alcohol and cannabis are combined [85]. 
Indeed, greater information on the pharmacokinetic effects of cannabis on driving is needed, 
together with other drug interactions. One difficult problem for roadside testing remains that 
current cannabis detection through breath, saliva, blood or urine does not provide a reliable 
measure of recency or potency of use.
8. Future directions in CUD research
A fundamental question in cannabis research is whether observed alterations in neurobiology 
and cognition with heavy cannabis use persist with abstinence or whether they are reversible. 
The neurobiological studies are currently limited by an absence of standardized methods 
to characterize cannabis consumption levels as well as compound composition. The vary-
ing compounds in cannabis samples present a challenge to conducting systematic cannabis 
research; it is unknown how all of these might interact [28] and varying cannabinoid levels 
across studies may account for the diverse findings reported in the literature. Most studies 
rely on self-report measures of cannabis use and those that do toxicology analyses provide 
poor measures for quantifying exposure or the timeframe. Additionally, different measures of 
intake (i.e., inhaling, vaping, with/without tobacco) can also influence THC release/metabo-
lism. Given all of the uncertainty between exposure parameters and neural substrates, many 
researchers are now calling for standardization of cannabis use metrics, particularly as the 
drug’s effects appear more closely linked to dosage than duration of use [49]. Questions 
for future research include: (1) understanding CB1 receptor changes and relationships with 
reward, motivation, craving and abstinence, (2) clarifying cognitive and motivational altera-
tions and whether these are precursors or consequences of CUD and (3) understanding the 
links between cannabis use and psychotic disorders. In this changing political, social, psycho-
pharmacological and compositional landscape of cannabis, understanding the harms associ-
ated with cannabis use and CUD will be fundamental in informing policy and supporting 
clinicians.
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